Elicio Therapeutics to Present at H.C. Wainwright 26th Annual Conference

BOSTON, Aug. 28, 2024 — Elicio Therapeutics (Nasdaq: ELTX), a biotechnology company at the clinical stage, is set to exhibit its advanced immunotherapy developments aimed at cancer treatment. Robert Connelly, the Chief Executive Officer of Elicio Therapeutics, will deliver a presentation at the H.C. Wainwright 26th Annual Global Investment Conference. This event is scheduled for September 11, 2024, at 2:30 p.m. Eastern Time.

The presentation will be accessible through a live webcast for registered attendees via Elicio’s Events page. Additionally, an archived replay will be available on-demand for 90 days following the presentation.

Elicio Therapeutics, Inc., listed on Nasdaq under the ticker ELTX, focuses on creating innovative lymph node-targeted immunotherapies to combat highly aggressive cancers. The company leverages its expertise in immunology and immunotherapy to harness the immune system's innate power through its AMP technology. This technology is designed to deliver therapeutic payloads directly to the lymph nodes, thereby aiming to bolster the immune system's ability to fight cancer.

The core of Elicio's approach involves targeting cancer immunotherapies to the lymph nodes, which play a vital role in educating, activating, and amplifying cancer-specific T cells. These T cells are crucial for identifying and destroying tumor cells. The AMP technology is engineered to synchronize immunity within these potent sites, enhancing the immune response's magnitude, potency, quality, and durability to drive antitumor activity.

Elicio’s research and development pipeline includes several promising candidates. Among them is ELI-002, an off-the-shelf therapeutic cancer vaccine targeting mKRAS-driven cancers. Additionally, the pipeline features ELI-007 and ELI-008, which target BRAF-driven cancers and p53 hotspot mutations, respectively.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!